|
Use of Nucleotide Synthesis Inhibitors for Targeted Therapy in MLL3/4 COMPASS Mutant Cancer
NU 2022-053
INVENTORS
Ali Shilatifard (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)*
Zibo Zhao (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)*
SHORT DESCRIPTION
A therapeutic platform that targets MLL3/4 COMPASS mutant cancers by using nucleotide synthesis inhibitors to disrupt...
Published: 5/26/2026
|
Updated: 4/29/2026
|
Inventor(s):
Keywords(s): Bladder cancer, Breast cancer, Cancer/Oncology, Colon cancer, Gastric cancer, Leukemia, Lung cancer, Lymphoma, Prostate cancer, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION
Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy.
INVENTORS
Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*
Jindan...
Published: 5/6/2026
|
Updated: 3/5/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Therapy for T-Cell Lymphoma
NU2022-104
INVENTORS
Jaehyuk Choi*
Jay Daniels
Jurgen Ruland
Tim Wartweig
SHORT DESCRIPTION
Targeting PD-1 related mechanisms for treatment of aggressive T-Cell lymphomas
BACKGROUND
T-cell non-Hodgkin lymphomas (T-NHLs) are highly aggressive cancers that can be resistant to chemotherapies. The molecular pathogenesis of these cancers remains...
Published: 12/15/2025
|
Updated: 5/14/2024
|
Inventor(s):
Keywords(s): Cancer/Oncology, Lymphoma, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|